Fibroblast growth factor 2 induces mesenchymal stem cells to differentiate into tenocytes through the MAPK pathway

Cai,Tao-Yi; Zhu,Wei; Chen,Xiong-Sheng; Zhou,Sheng-Yuan; Jia,Lian-Shun; Sun,Yan-Qing

doi:10.3892/mmr.2013.1668

Fibroblast growth factor 2 induces mesenchymal stem cells to differentiate into tenocytes through the MAPK pathway

Authors:
- Tao-Yi Cai
- Wei Zhu
- Xiong-Sheng Chen
- Sheng-Yuan Zhou
- Lian-Shun Jia
- Yan-Qing Sun
View Affiliations

Affiliations: Department of Orthopedic Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, P.R. China
Published online on: September 4, 2013 https://doi.org/10.3892/mmr.2013.1668
Pages: 1323-1328

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesenchymal stem cells (MSCs) differentiate into numerous different cell types and thus have therapeutic potential for tissue engineering, anti‑inflammatory and immunomodulatory purposes. FGF2 may affect the biological behavior of MSCs. MSCs were transduced with either adenovirus‑null vector/green fluorescent protein (GFP) or a vector encoding for the overexpression of FGF2/GFP. The expression of FGF2 was demonstrated to be significantly higher in MSC (FGF2) compared with MSC (vector) by qPCR and western blot analysis. In order to investigate the function of FGF2 in MSCs over time, it was observed that FGF2 stimulates cell proliferation and induces cell differentiation by activating the mitogen‑activated protein kinase (MAPK) signaling pathway. Following blockade of the FGF2‑induced activation of the extracellular signal‑regulated kinase pathway by overexpression of sprouty isoforms, the marker of differentiation markedly decreased. Altogether, the results demonstrated a novel cell biological mechanism that FGF2 differentiates into tenocytes and the MAPK pathway is key in differentiation.

View Figures

View References

1	Rees JD, Wilson AM and Wolman RL: Current concepts in the management of tendon disorders. Rheumatology (Oxford). 45:508–521. 2006. View Article : Google Scholar : PubMed/NCBI
2	Järvinen TA, Kannus P, Maffulli N and Khan KM: Achilles tendon disorders: etiology and epidemiology. Foot Ankle Clin. 10:255–266. 2005.
3	Wang JH, Iosifidis MI and Fu FH: Biomechanical basis for tendinopathy. Clin Orthop Relat Res. 443:320–332. 2006. View Article : Google Scholar : PubMed/NCBI
4	Hoffmann A and Gross G: Tendon and ligament engineering: from cell biology to in vivo application. Regen Med. 1:563–574. 2006. View Article : Google Scholar : PubMed/NCBI
5	Kuo CK, Marturano JE and Tuan RS: Novel strategies in tendon and ligament tissue engineering: Advanced biomaterials and regeneration motifs. Sports Med Arthrosc Rehabil Ther Technol. 2:202010. View Article : Google Scholar : PubMed/NCBI
6	Bruder SP, Fink DJ and Caplan AI: Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. J Cell Biochem. 56:283–294. 1994. View Article : Google Scholar
7	Jorgensen C, Gordeladze J and Noel D: Tissue engineering through autologous mesenchymal stem cells. Curr Opin Biotechnol. 15:406–410. 2004. View Article : Google Scholar : PubMed/NCBI
8	Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62:3603–3608. 2002.PubMed/NCBI
9	Khakoo AY, Pati S, Anderson SA, et al: Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med. 203:1235–1247. 2006.PubMed/NCBI
10	Wu X, Chen S, Orlando SA, et al: p85alpha regulates osteoblast differentiation by cross-talking with the MAPK pathway. J Biol Chem. 286:13512–13521. 2011. View Article : Google Scholar : PubMed/NCBI
11	Giuliani N, Bataille R, Mancini C, Lazzaretti M and Barillé S: Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 98:3527–3533. 2001. View Article : Google Scholar : PubMed/NCBI
12	Powers CJ, McLeskey SW and Wellstein A: Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 7:165–197. 2000. View Article : Google Scholar : PubMed/NCBI
13	Yu PJ, Ferrari G, Galloway AC, Mignatti P and Pintucci G: Basic fibroblast growth factor (FGF-2): the high molecular weight forms come of age. J Cell Biochem. 100:1100–1108. 2007. View Article : Google Scholar : PubMed/NCBI
14	van den Bos C, Mosca JD, Winkles J, Kerrigan L, Burgess WH and Marshak DR: Human mesenchymal stem cells respond to fibroblast growth factors. Hum Cell. 10:45–50. 1997.PubMed/NCBI
15	Tsutsumi S, Shimazu A, Miyazaki K, et al: Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem Biophys Res Commun. 288:413–419. 2001. View Article : Google Scholar : PubMed/NCBI
16	Bianchi G, Banfi A, Mastrogiacomo M, et al: Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res. 287:98–105. 2003. View Article : Google Scholar : PubMed/NCBI
17	Baddoo M, Hill K, Wilkinson R, et al: Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J Cell Biochem. 89:1235–1249. 2003. View Article : Google Scholar : PubMed/NCBI
18	Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ and Lim DS: Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways. Stem Cells Dev. 17:725–736. 2008. View Article : Google Scholar : PubMed/NCBI
19	Masola V, Gambaro G, Tibaldi E, et al: Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem. 287:1478–1488. 2012. View Article : Google Scholar
20	Solchaga LA, Penick K, Porter JD, Goldberg VM, Caplan AI and Welter JF: FGF-2 enhances the mitotic and chondrogenic potentials of human adult bone marrow-derived mesenchymal stem cells. J Cell Physiol. 203:398–409. 2005. View Article : Google Scholar : PubMed/NCBI
21	Varas L, Ohlsson LB, Honeth G, et al: Alpha10 integrin expression is up-regulated on fibroblast growth factor-2-treated mesenchymal stem cells with improved chondrogenic differentiation potential. Stem Cells Dev. 16:965–978. 2007. View Article : Google Scholar
22	Neubauer M, Fischbach C, Bauer-Kreisel P, et al: Basic fibroblast growth factor enhances PPARgamma ligand-induced adipogenesis of mesenchymal stem cells. FEBS Lett. 577:277–283. 2004. View Article : Google Scholar : PubMed/NCBI
23	Lai WT, Krishnappa V and Phinney DG: Fibroblast growth factor 2 (Fgf2) inhibits differentiation of mesenchymal stem cells by inducing Twist2 and Spry4, blocking extracellular regulated kinase activation, and altering Fgf receptor expression levels. Stem Cells. 29:1102–1111. 2011. View Article : Google Scholar
24	Frederick JP, Liberati NT, Waddell DS, Shi Y and Wang XF: Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol. 24:2546–2559. 2004. View Article : Google Scholar
25	Wang L, Blouin V, Brument N, Bello-Roufai M and Francois A: Production and purification of recombinant adeno-associated vectors. Methods Mol Biol. 807:361–404. 2011. View Article : Google Scholar : PubMed/NCBI
26	Lanner F and Rossant J: The role of FGF/Erk signaling in pluripotent cells. Development. 137:3351–3360. 2010. View Article : Google Scholar : PubMed/NCBI
27	Ozaki K, Miyazaki S, Tanimura S and Kohno M: Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. J Cell Sci. 118:5861–5871. 2005. View Article : Google Scholar : PubMed/NCBI